Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 EV-to-FCF is 0.88 as of Jul. 31, 2026, which is 85% below its 10-year median of 5.81. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,193 Consumer Packaged Goods companies, Integrated Biopharma ranks better than 96.65% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Integrated Biopharma's Enterprise Value is $2.49 Mil.
Integrated Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $2.83 Mil. Therefore, Integrated Biopharma's EV-to-FCF for today is 0.88.
The historical rank and industry rank for Integrated Biopharma's EV-to-FCF or its related term are showing as below:
INBP'
s EV-to-FCF Range Over the Past 10 Years
Min: -12628.69 Med: 5.81 Max: 520.8
Current: 0.88
During the past 13 years, the highest EV-to-FCF of Integrated Biopharma was 520.80. The lowest was -12628.69. And the median was 5.81.
INBP's EV-to-FCF is ranked better than 96.65% of 1193
companies
in the Consumer Packaged Goods industry
Industry Median: 16.01
vs INBP: 0.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Integrated Biopharma's PE Ratio (TTM) for today is calculated as:
Integrated Biopharma's share price for today is $0.16.
Integrated Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Integrated Biopharma EV-to-FCF Related Terms
Integrated Biopharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Integrated Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Integrated Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma EV-to-FCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's EV-to-FCF falls into.
Integrated Biopharma's current Enterprise Value is $2.49 Mil.
Integrated Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma (INBP) has a EV-to-FCF of 0.88 as of Jul. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Integrated Biopharma and its competitors. This is 85% below median its historical median of 5.81. According to the industry distribution chart, Integrated Biopharma ranks #40 out of 1193 companies in the Consumer Packaged Goods industry, placing it in the top 3.4%.
Is Integrated Biopharma's EV-to-FCF too high?
Integrated Biopharma's current EV-to-FCF of 0.88 is 85% below median its 10-year median of 5.81. The Consumer Packaged Goods industry median EV-to-FCF is 16.01. Integrated Biopharma's value of 0.88 is 94.5% below this industry median. Based on the distribution chart, Integrated Biopharma ranks #40 out of 1193 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's EV-to-FCF compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #40 out of 1193 companies for EV-to-FCF. This places Integrated Biopharma in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.01. Integrated Biopharma's value of 0.88 is 94.5% below this benchmark. While the company's 10-year median is 5.81 vs. the industry median of 16.01, Integrated Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Consumer Packaged Goods company?
The median EV-to-FCF among Consumer Packaged Goods companies is 16.01, based on 1,193 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Biopharma's current EV-to-FCF of 0.88 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median EV-to-FCF is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current EV-to-FCF is 0.88, which is 85% below median its own 10-year median of 5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current EV-to-FCF is 0.88, which is 85% below median its 10-year median of 5.81 and 94.5% below the Consumer Packaged Goods industry median of 16.01. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current EV-to-FCF is 0.88 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
EV-to-FCF: 0.88 (85% below median its 10-year median of 5.81)
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
Industry Position: 94.5% below the Consumer Packaged Goods median (#40 of 1193)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
